ISHL12 2022 | The importance of balancing efficacy & toxicity when selecting treatment approaches in frontline HL
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, summarizes the different approaches used to treat patients with Hodgkin lymphoma (HL) and the importance of balancing efficacy and toxicity when selecting between these regimens. Dr Collins first highlights that escalated BEACOPP regimens are highly efficacious, albeit associated with increased short-term toxicity, whereas regimens consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) have relatively lower rates of efficacy and toxicity. Finally, Dr Collins explains that AVD + brentuximab vedotin treatment has an intermediate toxicity and efficacy profile. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Received honoraria for speaker and advisory work from:
Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio
Received research funding from:
BMS, MSD, Pfizer, Amgen, Celgene, Beigene
